Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Keymed Biosciences, Inc. ( (HK:2162) ) has shared an announcement.
Keymed Biosciences will exit its roughly 15% minority stake in Ouro Medicines after the U.S. biotech is acquired via a merger for up to US$2.175 billion, comprising US$1.675 billion upfront and as much as US$500 million in milestone-based contingent payments. Based on its shareholding, Keymed expects to receive about US$250 million upfront and potentially up to US$70 million in additional milestone payments, strengthening its balance sheet and signaling successful monetization of a non-core investment, though completion remains subject to customary regulatory and closing conditions and is classified as a discloseable transaction under Hong Kong listing rules.
The most recent analyst rating on (HK:2162) stock is a Hold with a HK$52.00 price target. To see the full list of analyst forecasts on Keymed Biosciences, Inc. stock, see the HK:2162 Stock Forecast page.
More about Keymed Biosciences, Inc.
Keymed Biosciences Inc. is a biopharmaceutical company listed in Hong Kong that invests in and develops innovative medicines, including through minority stakes in overseas drug developers. The group manages these holdings as financial assets at fair value, using strategic disposals and partnerships to optimize returns and support its broader pipeline and growth plans.
Average Trading Volume: 1,463,977
Technical Sentiment Signal: Buy
Current Market Cap: HK$14.32B
Find detailed analytics on 2162 stock on TipRanks’ Stock Analysis page.